- Home
- AUPH vs ERII Comparison
AUPH vs ERII Comparison
Compare AUPH & ERII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- ERII
- Stock Information
- Founded
- AUPH 1993
- ERII 1992
- Country
- AUPH Canada
- ERII United States
- Employees
- AUPH N/A
- ERII N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- ERII Industrial Machinery/Components
- Sector
- AUPH Health Care
- ERII Technology
- Exchange
- AUPH Nasdaq
- ERII Nasdaq
- Market Cap
- AUPH 1.4B
- ERII 762.9M
- IPO Year
- AUPH 1999
- ERII 2008
- Fundamental
- Price
- AUPH $12.30
- ERII $14.62
- Analyst Decision
- AUPH Strong Buy
- ERII Buy
- Analyst Count
- AUPH 3
- ERII 4
- Target Price
- AUPH $12.00
- ERII $18.75
- AVG Volume (30 Days)
- AUPH 1.5M
- ERII 369.5K
- Earning Date
- AUPH 11-06-2025
- ERII 10-29-2025
- Dividend Yield
- AUPH N/A
- ERII N/A
- EPS Growth
- AUPH N/A
- ERII 25.10
- EPS
- AUPH 0.42
- ERII 0.43
- Revenue
- AUPH $260,111,000.00
- ERII $141,775,000.00
- Revenue This Year
- AUPH $16.92
- ERII $6.16
- Revenue Next Year
- AUPH $14.43
- ERII $13.06
- P/E Ratio
- AUPH $29.12
- ERII $34.28
- Revenue Growth
- AUPH 25.59
- ERII 6.19
- 52 Week Low
- AUPH $6.55
- ERII $10.86
- 52 Week High
- AUPH $12.90
- ERII $20.27
- Technical
- Relative Strength Index (RSI)
- AUPH 56.77
- ERII 56.27
- Support Level
- AUPH $12.06
- ERII $14.20
- Resistance Level
- AUPH $12.90
- ERII $14.65
- Average True Range (ATR)
- AUPH 0.39
- ERII 0.35
- MACD
- AUPH -0.08
- ERII -0.01
- Stochastic Oscillator
- AUPH 54.89
- ERII 67.00
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About ERII Energy Recovery Inc.
Energy Recovery Inc is an engineering-driven technology company. It is engaged in engineering, designing, manufacturing and supplying solutions that make industrial processes more efficient and sustainable. The company operates in three segments, Water, Emerging Technologies and Corporate. It offers energy recovery devices (ERDs) and pumps as well as related products and services to the reverse osmosis desalination market. The company derives a majority of the revenue from the Water segment. Geographically, the company operates in the U.S. and other international countries.